High-Throughput Screening

In our fully automated laboratories, experienced scientists design and execute a wide range of perfectly miniaturized, cost-effective assays carefully adjusted to fit your needs. Our equipment enables large-scale screening of NUVISAN’s small-molecule compound library containing up to 3 million well-characterized compounds, as well as focused screening of smaller well-selected sub-libraries. At NUVISAN, we have more than 25 years of experience in performing large ultra-HTS campaigns using biochemical, biophysical, mass spectrometry, cellular, and phenotypic high-content assays.

Our scientists benefit from state-of-the-art instrumentation that enables flexible, customer-focused assay development and the acquisition of up to 400,000 data points per day in a 1,536-well format. The processing of the data volume is managed by cutting-edge data management systems (Genedata Screener; PerkinElmer Spotfire), enabling the best possible processing and provision of data to customers.

The NUVISAN screening team has extensive assay and screening expertise covering a wide range of target classes and mechanisms:

Screening Cascade for a Prototype Target-Based HTS Project (NUVISAN Library)

The screening cascade of an HTS project is custom tailored for every project. After identifying hits in the 3-million-compound library for the primary target assay, hit confirmation ensures that those hits are specific to the target and do not interfere with the detection system. Dose-response analysis in selectivity, biophysical, and cell-based assays, as well as LC-MS data, enable the selection of desired compound profiles for the validated hit list. Additional assessments from our MedChem experts and data from our Life Science Database support the selection process. On the way to the licensed hits, re-synthesis of selected cluster members and additional assays increase the confidence, creating a successful follow-up hit-to-lead program.

Proven Pipeline Impact of the HTS Library Available at NUVISAN for Your Project

Interested in more examples of hits identified in HTS by the NUVISAN team?


Göricke, F., et al., Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21. J Med Chem (2023)


Wortmann, L., et al., Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A. J Med Chem (2021)


Gradl, S., et al., Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening. SLAS Discov (2021)


Panknin, O., et al., Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women. J Med Chem (2020)


Lemos, C., et al., Identification of Small Molecules that Modulate Mutant p53 Condensation. iScience (2020)


Hillig, RC., et al., Discovery of Potent SOS1 Inhibitors That Block RAS Activation via Disruption of the RAS–SOS1 Interaction. PNAS (2019)

More NUVISAN literature